Compellis Pharmaceuticals, Inc. Awarded Second Broad Patent From the U.S. Patent Office for Novel Obesity Therapy

BOSTON, MA, Oct 27 (MARKET WIRE) --
Compellis Pharmaceuticals, an early-stage biopharmaceutical company
developing novel mechanism-based therapeutics for the treatment of
obesity, announced today that they have been issued a second broad patent
(7,138,107) by the U.S. Patent and Trademark Office (USPTO) for its
invention entitled "Inhibition of olfactory neurosensory function to
treat obesity and related disorders." The patent broadly protects key
aspects of Compellis' novel obesity therapeutic strategy. Compellis has
successfully demonstrated its therapeutic effect on weight gain in
pre-clinical animal models and the results are published in
"Pharmacology, Biochemistry and Behavior."

"This second patent issuance significantly broadens the company's
intellectual property portfolio and is a valuable asset for its obesity
therapeutic platform," said Chris Adams, president and CEO of Compellis
Pharmaceuticals. "This second patent expands the scope of the company's
invention by protecting a broad class of calcium channel antagonists to
treat obesity. This includes all new and existing molecules, covering both
methods and composition of matter. This second patent greatly enhances the
commercial potential of Compellis' obesity therapeutic strategy. The next
step in development is completion of human testing with CP404."

CP404 is a calcium channel blocker used in a nasal formulation to block
olfactory activity and reduce food intake. Compellis has tested a series
of like compounds and the effect can be seen in the overall class of
calcium channel blockers. The advantage of CP404 is that because it is a
small molecule, it is well-tolerated in man and is readily manufactured.
Based on its prior use in humans for certain other disorders, Compellis
believes some of the drawbacks typically associated with unproven
compounds will not be an issue with CP404. The result is a focused
clinical development process that may result in a faster time to market.

About Compellis Pharmaceuticals, Inc.

Compellis Pharmaceuticals, an early-stage biopharmaceutical company
developing novel mechanism-based therapeutics for the treatment of
obesity. The company reformulates FDA approved products and identifies
proprietary delivery methods to treat broad metabolic disorders. For more
information, please visit www.compellis.com.

For more information contact:
Chris Adams
President and CEO
Compellis Pharmaceuticals, Inc.
617-957-9858
cadams@compellis.com

Copyright 2008, Market Wire, All rights reserved.

-0-